Edition:
United States

Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

46.80USD
15 Dec 2017
Change (% chg)

$0.51 (+1.10%)
Prev Close
$46.29
Open
$46.71
Day's High
$46.95
Day's Low
$46.33
Volume
764,575
Avg. Vol
369,292
52-wk High
$47.37
52-wk Low
$27.94

Chart for

About

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical... (more)

Overall

Beta: 1.29
Market Cap(Mil.): $1,928.70
Shares Outstanding(Mil.): 41.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Emergent Biosolutions reports third quarter results

* Emergent Biosolutions reports third quarter and nine months 2017 financial results; raises calendar year 2017 guidance

Nov 02 2017

BRIEF-Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 mln to supply nerve agent antidote auto-injector

* Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 million to supply nerve agent antidote auto-injector

Oct 04 2017

BRIEF-Emergent Biosolutions completes acquisition of Raxibacumab from GSK​

* Emergent Biosolutions Inc - ‍transaction anticipated to be additive by approximately $9 million to revenue and neutral to GAAP net income for full year 2017​

Oct 03 2017

BRIEF-Emergent BioSolutions signs five-year follow-on contract with DoD valued at up to $171 mln​

* Emergent BioSolutions to supply DoD with chemical threat countermeasure RSDL under five-year follow-on contract valued at up to $171 million

Sep 25 2017

BRIEF-Emergent BioSolutions awarded $63 mln BARDA contract to develop treatment for cyanide exposure

* Emergent BioSolutions - awarded contract valued at about $63 mln by Biomedical Advanced Research And Development Authority

Sep 18 2017

BRIEF-Emergent Biosolutions Q2 earnings per share $0.11

* Emergent Biosolutions reports second quarter and six months 2017 financial results; reaffirms calendar year 2017 guidance

Aug 03 2017

BRIEF-Emergent Biosolutions awarded $23 mln to develop novel multi-drug auto-injector for U.S. Department Of Defense

* Emergent Biosolutions awarded $23 million to develop novel multi-drug auto-injector for U.S. Department of defense Source text for Eikon: Further company coverage:

Jul 31 2017

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

* Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

Jul 26 2017

BRIEF-Emergent Biosolutions to acquire Raxibacumab from GSK

* Emergent Biosolutions to acquire Raxibacumab, an FDA-approved Anthrax monoclonal antibody, from GSK

Jul 19 2017

BRIEF-Emergent Biosolutions updates terms of termination of agreement related to acquisition of Sanofi's acam2000 business

* Emergent Biosolutions updates on terms of any termination of agreement related to acquisition of acam2000 business from Sanofi

Jul 14 2017

Competitors

Earnings vs. Estimates